Phase III dose‐comparison study of glatiramer acetate for multiple sclerosis
Article 2010 en
Authors
GC
Giancarlo Comi
JC
Jeffrey A. Cohen
DA
Douglas L. Arnold
Abstract
1 min read
In relapsing-remitting MS patients, both the currently-approved GA 20 mg and 40 mg doses were safe and well-tolerated, with no gain in efficacy for the higher dose.
Discussion(0)
No comments yet. Be the first to comment.